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Abstract
Two major infectious forms of vaccinia virus (VACV) have been described: the intracellular mature virion (IMV), and the extracellular
enveloped virion (EEV). Due to their stability in the environment, IMVs play a predominant role in host-to-host transmission, whereas EEVs
play an important role in dissemination within the host. In a previous report, we demonstrated that mice vaccinated with VACV L1R (IMV
immunogen) and A33R (EEV immunogen) were protected from a lethal poxvirus challenge. Vaccination with a combination of both genes
conferred greater protection than either gene alone, suggesting that an immune response against both IMV and EEV is advantageous. Here,
we report that in mice individually administered DNA vaccines with two different VACV immunogens, A27L (IMV immunogen) or B5R
(EEV immunogen), failed to significantly protect; however, vaccination with a combination of both genes conferred a high level of
protection. Mice were completely protected when vaccinated with a combination of four VACV genes (A27L  A33R  L1R  B5R).
Rhesus macaques vaccinated with this four-gene-combination developed appropriate antibody responses to each protein. Antibody
responses elicited by this vaccine cross-reacted with monkeypox virus orthologous proteins. These data indicate that a gene-based vaccine
comprised of the VACV A27L  A33R  L1R  B5R genes may be a useful candidate to protect against other orthopoxviruses, including
those that cause monkeypox and smallpox.
Published by Elsevier Science (USA).
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Introduction
The vaccine used by the World Health Organization to
eradicate naturally occurring smallpox disease consists of
live vaccinia virus administered by scarification. This vac-
cine is still used today to protect laboratory workers from
accidental VACV infection, and has also been stockpiled as
a defense against new poxvirus outbreaks, especially an
accidental or malicious re-introduction of smallpox. Despite
their great importance, the VACV immunogens that protect
against variola virus, the causative agent of smallpox, re-
main largely unknown. Our goal has been to identify pro-
tective VACV immunogens and then to use this information
to augment poxvirus countermeasures.
Vaccinia, genus orthopoxvirus, family Poxviridae, is a
large (200 nm) virus containing a linear double-stranded
DNA genome of 200 kbp encoding 250 genes (re-
viewed in Moss, 2001). Other orthopoxviruses share signif-
icant homology with vaccinia. For example, variola virus
and vaccinia share 150 open reading frames with 90%
amino acid identity (Goebel et al., 1990; Massung et al.,
1994). There are two infectious forms of poxviruses, the
intracellular mature virion (IMV) and the extracellular en-
veloped virion (EEV). The poxviral IMV assembles in the
cytoplasm and consists of a core particle, which contains the
genome and numerous enzymes, wrapped in a membrane.
At least 11 proteins are associated with the proteinaceous
IMV surface membrane: A14.5L (p 10 kDa) (Betakova et
al., 2000), E10R (p12 kDa) (Senkevich et al., 2000), I5L
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(p13 kDa) (Takahshi et al., 1994), A13L (p14 kDa) (Taka-
hashi et al., 1994; Salmons et al., 1997), A27L (p14 kDa)
(Rodriguez and Esteban, 1987), A9L (p  18 kDa) (Yeh et
al., 2000), A14L (p17–25 kDa) (Takahshi et al., 1994),
A17L (p23–29 kDa) (Takahshi et al., 1994), and L1R
(p25–29 kDa) (Franke et al., 1990), D8L (p34 kDa) (Niles
and Seto, 1988), and H3L (p35 kDa) (Chertov et al., 1991).
As IMV accumulate, they can be released from dying cells
or alternatively can be wrapped in additional trans-Golgi-
derived membranes and released from the infected cells as
EEV. At least five proteins are associated with the EEV
lipid bilayer membrane: A33R (gp23–28) (Roper et al.,
1996), A34R (gp22–34 kDa) (Duncan and Smith, 1992),
F13L (p37 kDa) (Hirt et al., 1986), B5R (gp42 kDa) (En-
gelstad et al., 1992; Isaacs et al., 1992), and A56R (gp85
kDa hemagluttinin) (Shida, 1986). A36R (p43–50) was pre-
viously thought to be associated with the EEV membrane
(Parkinson and Smith, 1994); however, a recent report pro-
vides evidence that A36R is a component of the membrane
that wraps intracellular enveloped particles within the cell
but is not associated with EEV released from the infected
cell (van Eijl et al., 2000). Similarly, F12L (p65 kDa) was
found to co-purify with EEV; however, it remains to be
determined if this protein is a component of EEV particles
(Zhang et al., 2000). Some EEV remain attached to the cell
surface and play a role in short-range cell-to-cell spread.
Some are released into the medium and play a role in
long-range dissemination within the host (Payne, 1980;
Blasco and Moss, 1992).
Individual vaccinia genes have been cloned, expressed in
Escherichia coli, or in baculovirus systems, and the exog-
enously expressed proteins have been tested for immuno-
genicity and protective efficacy in mice. Lai et al. (1991)
demonstrated that vaccination with the E. coli-expressed
A27L elicited neutralizing antibodies (NAbs) and protected
mice against a lethal challenge with vaccinia. Demkowicz et
al. (1992) confirmed that vaccination with E. coli-expressed
A27L completely protected mice, and also demonstrated
that vaccination with the core proteins A10L or A4L was
partially protective. Galmiche et al. (1999) demonstrated
that vaccination with baculovirus-expressed EEV proteins,
B5R or A33R, protected mice against a lethal vaccinia
challenge, whereas vaccination with E. coli-expressed
A34R or A36R did not.
DNA vaccination technology has also been used to eval-
uate the immunogenicity and protective efficacy of individ-
ual vaccinia endogenously expressed proteins. DNA vacci-
nation with A33R or B5R, but not A34R or A36R, protected
mice against a lethal intranasal (i.n.) challenge with the
IHD-J strain of vaccinia (Galmiche et al., 1999). We pre-
viously demonstrated that DNA vaccination of mice with a
combination of IMV and EEV genes (L1R and A33R,
respectively) protected mice from challenge (strain WR,
intraperitoneal [i.p.] route) more effectively than vaccina-
tion with either gene alone (Hooper et al., 2000).
The mechanisms by which the aforementioned VACV
immunogens (L1R, A27L, A33R, B5R, A10L, A4L) confer
protective immunity against vaccinia in mice are not com-
pletely known. Targets of IMV-neutralizing antibodies in-
clude proteins encoded by five of the 11 known IMV genes:
A27L (Rodriguez and Esteban, 1987), L1R (Ichihashi et al.,
1994 [misidentified as A17L]; Wolffe et al., 1995), D8L
(Hsiao et al., 1999), H3L (Gordon et al., 1991 [misidentified
as H6R]), and A17L (Wallengren et al., 2001). Passive
transfer data for L1R-, D8L-, H3L-, and A17L-specific
antibodies have not been reported; however, we have un-
published data demonstrating that passive transfer of a L1R-
specific MAb, MAb-7D11, 1 day before challenge, pro-
tected BALB/c mice from a lethal challenge (VACV-WR,
i.p.). There have been at least three reports that A27L-
specific monoclonal antibodies (MAbs) can protect mice in
passive transfer experiments (Czerny and Mahnel, 1990;
Czerny et al., 1994; Ramirez et al., 2002). One EEV gene,
B5R, has been reported to be the target of antibodies that
neutralize EEV (Galmiche et al., 1999; Law and Smith,
2001). Passive transfer of anti-B5R hyperimmune mouse or
rabbit sera protected 40–60% of mice challenged i.n. with
vaccinia, strain IHD-J (Galmiche et al., 1999) Thus, it is
possible that IMV or EEV neutralization plays a role in
protection observed after vaccination with L1R, A27L, or
B5R. Passive transfer of anti-A33R hyperimmune mouse
sera, but not rabbit sera, protected 80% of mice challenged
i.n. with vaccinia, strain IHD-J (Galmiche et al., 1999). The
non-neutralizng anti-A33R response might elicit protection
by directing lysis of infected cells. In support of this, an
A33R-specific MAb (MAb-1G10) directed lysis of vaccin-
ia-infected cells in the presence of guinea pig complement,
as measured by chromium release assay (A. Schmaljohn,
unpublished data). The mechanism underlying the partial
protection observed in mice vaccinated with the core pro-
teins A10L and A4L is unknown, but likely involves cell-
mediated-immunity (Demkowicz et al., 1992).
In our previous study, DNA vaccination with a combi-
nation of L1R and A33R not only conferred complete pro-
tection, but also appeared to protect nearly as well as scar-
ification with live VACV as measured by prevention of
weight loss (Hooper et al., 2000). We hypothesized that the
high level of protection was due to the fact that immune
responses generated by this combination vaccine targeted
the infection at several levels. IMV introduced in the initial
challenge, as well as IMV released from infected cells, was
neutralized by L1R-specific NAbs; and A33R-specific an-
tibodies targeted the EEV and possibly infected cells ex-
pressing A33R on their surfaces.
The objective of our work was to further test DNA
vaccines comprised of different combinations of IMV and
EEV immunogens for immunogenicity and protective effi-
cacy in mice, and expand this work into nonhuman pri-
mates.
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Results
Cloning the VACV A27L and B5R genes into a naked-
DNA vector and transient expression in cell culture
The A27L and B5R genes from vaccinia virus, NYBH
strain Connaught (VACV-CONN), were cloned into the
DNA vaccine plasmid pWRG7077 to create constructs
pWRG/A27L and pWRG/B5R, respectively. Radio-immu-
noprecipitation experiments were performed to evaluate the
expression products. The predicted 14 kDa and 42 kDa
proteins were expressed from pWRG/A27L and pWRG/
B5R, respectively (data not shown).
DNA vaccination of mice with pWRG/B5R elicits a non-
NAb response, and vaccination with pWRG/A27L elicits a
NAb response
To determine the immunogenicity of the expression
products, groups of nine mice each were vaccinated with
pWRG/A27L or pWRG/B5R with a gene gun (experiment
1). The mice were vaccinated at weeks 0, 3, and 5. As
positive controls, nine mice were vaccinated by tail scari-
fication with VACV-CONN. Serum was collected 2 weeks
after the third DNA vaccination, or 8 weeks after scarifica-
tion, and tested for the presence of antibodies against B5R
or A27L (Fig. 1). All mice vaccinated with pWRG/B5R
developed vaccinia-specific antibodies as measured by a
vaccinia-infected-cell-lysate ELISA (geometric mean end-
point titer [GMT]  1728; range, 200–12800) (Fig. 1A),
and eight of nine were positive by a B5R-specific ELISA
(GMT  588; range  200–1600) (Fig. 1B). Only eight of
nine scarified mice developed a B5R-specific antibody re-
sponse and the response was twofold lower than the re-
sponses in the DNA-vaccinated mice, as measured by B5R-
specific ELISA (GMT 246; range 200–400) (Fig. 1B);
however, all samples were positive on the vaccinia infected-
cell-lysate ELISA (GMT  14703; range 6400–25600)
(Fig. 1A). All of the A27L-vaccinated mice had anti-vac-
cinia antibodies as measured by a vaccinia infected-cell-
lysate ELISA (GMT  2540; range 200–6400); moreover,
all of the mice produced IMV-neutralizing antibodies
(PRNT50 GMT  470, range 40–1280) as measured by
PRNT (Fig. 1C). All of the scarified mice developed NAbs
(PRNT50 GMT  1174, range 640–2560) (Fig. 1C). The
B5R-vaccinated mice did not develop NAb as measured by
our PRNT (data not shown); however, it should be noted
that the PRNT used in this study measures antibodies that
neutralize IMV but not EEV. Thus, our B5R and A27L
DNA vaccine plasmids were immunogenic in BALB/c
mice.
DNA vaccination of mice with a combination of both
A27L and B5R elicits better protection than vaccination
with either immunogen alone
To determine if the response elicited by pWRG/A27L or
pWRG/B5R was protective, we performed a second exper-
iment (experiment 2) in which mice were vaccinated with
Fig. 1. Antibody responses elicited by gene gun vaccination with pWRG/A27L or
pWRG/B5R. Sera from vaccinated mice were tested for vaccinia-specific antibod-
ies using (A) vaccinia-infected-cell-lysate ELISA, and (B) B5R-specific ELISA.
The mean O.D. values and standard deviations for the nine mice in each group are
shown. (C) PRNT were performed on sera from mice vaccinated with pWRG/
A27L (solid lines) or scarified (dashed lines) to evaluate the vaccinia-neutralizing
antibody response. Representative serum samples diluted 1:40 from mice vacci-
nated with a negative control plasmid are shown as symbols.
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plasmids alone, or in combination, and then challenged. The
mice were vaccinated at weeks 0, 3, and 5. A group of 10
mice vaccinated with an irrelevant plasmid served as the
negative control, and a group of VACV-scarified mice was
the positive control. We also vaccinated a group of mice
with a combination of four plasmids: two IMV genes, A27L
and L1R; and two EEV genes, B5R and A33R. Three weeks
after the final vaccination, serum was collected and the mice
were challenged with vaccinia. Serum collected on the day
of challenge was evaluated for immunogen-specific anti-
body responses (Fig. 2A). All of the mice vaccinated with
pWRG/A27L alone developed NAbs (PRNT50 GMT 
486), but only one of 10 survived challenge. Similarly, all of
the mice vaccinated with pWRG/B5R developed anti-B5R
antibodies (GMT  2111), but only four of 10 survived
challenge. In contrast, all of the mice vaccinated with a
combination of pWRG/A27L and pWRG/B5R developed
antibodies to both immunogens, and all survived challenge.
Similarly, all of the mice vaccinated with the four-gene
combination survived. Nine of 10 negative control mice
died and all of the positive control mice survived Fig. 2A.
As part of the same experiment, we also tested four other
immunogen combinations (groups 7–10, Fig. 2B). For the
IMV/EEV combinations, 10 of 10 mice vaccinated with
B5R L1R, and seven of 10 mice vaccinated with A27L
A33R, survived challenge. Only four of 10 mice vaccinated
with the two IMV immunogens, A27L  L1R, survived.
Eight of 10 mice vaccinated with the two EEV immuno-
gens, B5R  A33R survived.
To confirm and expand our findings in mice, we per-
formed a third experiment (experiment 3) where we re-
peated groups 1–6 (see Figure 2B), vaccinated with L1R
alone, and vaccinated a group of mice with cartridges that
contained all four genes precipitated on different gold beads
(see Methods). Mice were vaccinated at weeks 0, 3, and 6,
and then challenged 3 weeks after the third vaccination. In
experiment 3, the scarified controls were vaccinated 3
weeks before challenge.
Antibody responses were measured by PRNT or by in-
fected-cell-lysate ELISA (Fig. 2C). All of the mice vacci-
nated with A27L developed NAb as measured by PRNT,
GMT  470. All of the mice vaccinated with either A27L
or B5R developed antibodies as measured by infected-cell-
lysate ELISA. Fewer than half of the mice vaccinated with
either B5R or A27L alone were protected, whereas all but
one of the mice vaccinated with a combination of B5R and
A27L were protected (Fig. 2C). The mouse that died in this
group died later than controls (day 7) and appeared com-
pletely healthy on day 6. Whether each immunogen was
loaded in a separate cartridge or as a mixture in the same
cartridge, all 17 of the mice vaccinated with the four-gene-
combination (B5R  A27L  L1R  A33R) were pro-
tected. This experiment confirmed that vaccination with a
combination of A27L and B5R was protective, and vacci-
nation with A27L, B5R, L1R, and A33R, on the same or in
different cartridges, completely protected mice from a lethal
challenge.
DNA vaccination of mice with a combination of four
genes results in less weight loss than scarification, or
vaccination with combinations of two genes
For groups with 100% survival in experiment 2 (Fig. 2A
and 2B) and experiment 3 (Fig. 2C), weight loss was mea-
sured to determine the relative protective efficacy of the
different vaccines (Fig. 2D and 2E). Protected mice lost as
much as 12% of their initial weight during the first 1-3 days
after challenge. Mice vaccinated with the four-gene-combi-
nation lost the least amount of weight (8%) and regained
weight faster than mice in the other groups. Mice vaccinated
with live VACV-CONN by scarification lost the greatest
percentage of initial weight and regained the weight more
slowly. Although a few mice had slightly ruffed fur on days
1 and 2 after challenge, all of the mice vaccinated with the
four-gene-combinations shown in Fig. 2D and 2E regained
smooth fur within 3 days after challenge.
DNA vaccine is immunogenic in nonhuman primates
Two independent experiments were performed to deter-
mine if vaccination with the plasmids (pWRG/L1R 
pWRG/A27L  pWRG/A33R  pWRG/B5R) could elicit
antibody responses in nonhuman primates. In the first ex-
periment, three rhesus macaques were vaccinated with the
four-gene-combination. As negative controls, three mon-
keys were vaccinated with the vector plasmid containing
irrelevant DNA; and as positive controls, three monkeys
were vaccinated subcutaneously (s.c.) twice at 42-day in-
tervals with live vaccinia. The second experiment was iden-
tical to the first; however, an additional group of three
monkeys was vaccinated with pWRG/L1R alone, and the
positive control group was vaccinated with the human
smallpox vaccine (Dryvax) once by scarification by the
method used to vaccinate humans. Three weeks after the
fourth gene gun vaccination, serum was collected and tested
for the presence of specific antibodies. Six different sero-
logical assays were performed: PRNT, vaccinia-infected
cell lysate ELISA, vaccinia-virion ELISA, A33R-specific
immunostaining, B5R-specific immunostaining, and RIPA.
The results are shown in Fig. 3.
Of the six monkeys vaccinated with the four-gene com-
bination, three had NAbs, five were positive in the vaccinia-
infected cell lysate ELISA, and the same five were positive
by the vaccinia-virion ELISA. Five of the six monkeys had
B5R-specific antibodies and only three of six had A33R-
specific antibodies, as measured by immunostaining. The
RIPA was a more sensitive assay for detecting B5R- and
A33R-specific antibodies than ELISA or immunostaining.
Representative gels for monkeys vaccinated with DNA by
gene gun, live VACV by s.c., or scarification, are shown in
Fig. 3B. The RIPA results indicated that all six monkeys
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Fig. 2. Protection experiments in mice. (A–C) Mice were vaccinated with a DNA vaccine containing the indicated immunogen(s) or scarified with live
VACV-CONN. Sera were collected after the final vaccination and the animals were challenged i.p. with 5  108 PFU of VACV-WR. The prechallenge sera
were evaluated for NAbs by PRNT, and for anti-B5R or anti-A33R antibodies by protein-specific ELISA. In panel C an infected-cell-lysate ELISA was used
to measure anti-A27L and anti-B5R responses. PRNT and ELISA end-point titers for individual mice in each group are shown as bars. Filled bars represent
animals that did not survive challenge. Numbers to the right of filled bars indicate the day of death. In groups where positive antibody responses were detected,
geometric mean titers (GMT) are shown. NT, not tested. (D–E) For groups where all mice were protected, weight loss was used as a measure of relative
animal health. The average % of starting weight at times after challenge is shown. Panels A, B, and D contain data from challenge Experiment 2; panels C
and E contain data from challenge Experiment 3.
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vaccinated with the four-gene combination developed anti-
bodies to B5R and A33R. Monkey CH80 exhibited a very
weak response to all four genes.
All of the positive control monkeys had NAbs and were
positive by both vaccinia-infected cell lysate ELISA and
vaccinia-virion ELISA. Two of the monkeys vaccinated s.c.
with live VACV failed to develop levels of A33R-specific
antibody detectable by immunostaining, but RIPA revealed
there was a weak A33R response. Similarly, one monkey
vaccinated by scarification with Dryvax developed a B5R-
specific antibody response detectable only by RIPA, but not
by immunostaining.
We were unable to detect a L1R-specific antibody re-
sponse in any of the monkeys vaccinated with the four-
gene-combination, and the L1R response in monkeys vac-
cinated with live VACV was almost undetectable by
immunoprecipitation. To determine if the pWRG/L1R plas-
mid was immunogenic in monkeys, we vaccinated three
animals with L1R alone. All three monkeys developed
NAbs responses (Fig. 3A) and their sera immunoprecipi-
tated detectable levels of L1R expressed in cells transfected
with pWRG/L1R (Fig. 3C).
To prove that DNA vaccination of monkeys with pWRG/
L1R elicited an antibody response that could precipitate
authentic L1R, we performed RIPA in which serum from a
representative monkey vaccinated with pWRG/L1R was
used to immunoprecipitate the L1R protein from
VACV-WR infected-cell lyate. Serum from monkey CH63
precipitated a protein with the same apparent molecular
weight as that precipitated by a L1R-specific monoclonal
antibody (Fig. 4D). This band was not precipitated when
negative control antibodies were used.
Together, these data demonstrate that a candidate DNA
vaccine containing four vaccinia genes was immunogenic in
nonhuman primates. The NAb responses to the IMV immu-
nogens and the antibody responses to two EEV immuno-
gens in some, but not all, of the DNA vaccinated monkeys
were similar to those attained by vaccination with live
VACV.
VACV DNA vaccine elicits antibodies in nonhuman
primates that cross-react with monkeypox virus orthologs
In the future we plan to test the capacity of DNA vacci-
nation with this four-gene-combination (A27L  A33R 
L1R  B5R) to protect nonhuman primates against an
appropriate challenge. It is likely the challenge will involve
high dose i.v. injections of monkeypox virus, which has
been shown to cause severe, and sometimes lethal, monkey-
pox disease in rhesus monkeys (McConnel et al., 1964). We
were interested in determining if the antibody responses
elicited by vaccination with the VACV A27L, A33R, L1R,
or B5R genes would cross-react with the monkeypox virus
orthologs. To test this, we cloned the A27L, A33R, L1R and
B5R orthologous genes from monkeypox virus, strain Zaire
79 (MPOV-Z79), into pWRG7077 to yield plasmids: pM-
POX/A27Lo, pMPOX/A33Ro, pMPOX/L1Rho and pM-
POX/B5Ro, where ‘o’ indicates ortholog. The monkeypox
virus genes were sequenced and the amino acid sequences
were compared with the A27L, A33R, L1R, and B5R con-
tained in our VACV-CONN DNA vaccine plasmids (Fig.
4). Included in the comparison are sequences from: VACV-
WR, the virus used in our mouse challenge studies; a re-
cently published monkeypox virus, strain Zaire 96 (Shch-
elkunov et al., 2001); a variola major, strain India (VARV-
IND); and a variola minor, strain Garcia (VARV-GAR)
(Fig. 4). All of these viruses possess orthologs to the
VACV-CONN A27L, A33R, L1R and B5R, and all of the
genes are highly conserved. All of the proteins are at least
90% identical. Our VACV-CONN immunogens of interest
were all at least 93% identical to the MPOV and VARV
strains evaluated.
RIPA were performed to answer two questions: 1) Were
proteins of the predicted size produced from the plasmids
containing the four different monkeypox virus genes? and
2) Did antibody responses elicited by DNA vaccination with
plasmids containing the VACV-CONN A27L, A33R, L1R,
and B5R genes cross-react with the monkeypox virus or-
thologs? We transfected COS cells with the plasmids and
performed RIPA using serum from a monkey previously
vaccinated with the four vaccinia genes (monkey CH93).
Fig. 3. Candidate DNA vaccine elicits antibody responses against IMV and EEV in nonhuman primates. (A) Monkeys were vaccinated with a four-gene-
combination, L1R alone, live VACV by the s. c. route, or by scarification. PRNT were performed to evaluate the NAb response. The last dilution reducing
plaque number by either 50% or 80% are shown. Vaccinia-infected-cell lysate ELISA and vaccinia-purified virion ELISA were performed and the end-point
titers were determined. Anti-B5R and anti-A33R immunostaining assays were performed to determine the highest dilution of sera resulting in positive
protein-specific staining. Open bars were not expected to be positive and served as negative controls. For samples that were negative by immunostaining but
suspected to be positive, we performed RIPA. A  symbol above a bar indicates this sample was positive by RIPA, a / symbol indicates a weak band
was detected by RIPA, and a ? indicates the sample is negative by RIPA. (B) Representative RIPA data using sera from two monkeys vaccinated s.c. with
the four-gene-combination (RC114 and CH93), with live VACV (CH21 and AA016), or with live VACV by Dryvax scarification (CH86 and CH39) are
shown. Each lane represents a RIPA involving the indicated monkey serum and antigen in the form of cell lysate from cells transfected with a plasmid
expressing either L1R, A33R, B5R, A27L, or a control plasmid with no insert (); or cell lysate from COS cells infected with VACV-WR. A serum from
a naive monkey (normal sera) served as a negative control. L1R was not detected using these sera. (C) Sera from monkeys vaccinated with L1R alone (CH63,
CH74, and CH79) contained antibodies that immunoprecipitated L1R. L1R-specific MAb-7D11 served as a positive control. A  indicates immunopre-
cipitation from cells transfected with pWRG/L1R, and  indicates immunoprecipitation from cells transfected with a control plasmid with no insert,
pWRG7077. (D) Serum from a monkey vaccinated with L1R (CH63), or a negative control (CH85), or L1R-specific MAb-7D11, or a negative control
MAb-3d7 were tested by RIPA using VACV-WR infected-cell lysate as the source of antigen. A  indicates immunoprecipitation from cells infected with
VACV-WR, and  indicates immunoprecipitation from mock infected cells. Molecular mass markers (M) are shown in kDa on the left and the position of
specific vaccinia immunogens are shown on right.
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Fig. 4. Comparison of VACV, MPOV, and VARV A27L; A33R, L1R, and B5R orthologs. The amino acid sequences of the proteins encoded by our DNA vaccine
plasmids (VACV-CONN) were compared with VACV-WR, MPOV-Z79, MPOV-Z96, VARV-IND, and VARV-GAR orthologs. Amino acids that were identical
in all viruses are boxed in black. Positions where variation occurs are either shown boxed in gray (conserved substitutions), white (nonconserved substitutions), or
as a dash (deletion). Numbers at left are amino acid position. MPOV-Z79, MPOV- Z96, VACV-CONN, VACV-WR, VARV-IND, and VARV-GAR A27L ortholog
accession numbers are submitted AY160186, NP_536566, AY160184, P11258, NP_042178, and D72167, respectively; A33R ortholog accession numbers are
AY160188, NP_536572, AAF63733, BAA01805, CAA47507, and B72168, respectively; L1R ortholog accession numbers are submitted AY160187, NP_536507,
AAF63732, P07612, NP_042117, and 672159, respectively; B5R ortholog accession numbers are submitted AY160189, NP_536594, submitted AY160185,
Q01227, NP_042219, and E72150, respectively.
Serum from CH93 immunoprecipitated the MPOV-Z79
A33R, B5R, and A27L orthologs, but as in the case of the
vaccinia proteins, there were insufficient levels of L1R-
specific antibodies to immunoprecipitate the L1R ortholog.
To determine if pMPOX/L1Ro produced the correct pro-
tein, and to determine if the antibody response elicited by
vaccination with the VACV L1R was capable of cross-
reacting with the MPOV L1R ortholog, serum from a mon-
key vaccinated with the pWRG/L1R alone (monkey CH63)
was tested by RIPA. Serum from CH63 immunoprecipitated
the MPOV-Z79 L1R ortholog (Fig. 5). Thus, antibodies
elicited by vaccination with the VACV A27L, A33R, L1R,
and B5R bind to the orthologous proteins of monkeypox
virus.
We tested the capacity of the serum from DNA vacci-
nated monkeys to cross-neutralize monkeypox virus. Serum
from a representative monkey vaccinated with the four-
gene-combination or pWRG/L1R alone, CH93 and CH63,
respectively, was evaluated in a monkeypox virus PRNT.
We also tested serum from a monkey vaccinated by scari-
fication with VACV (Dryvax) (monkey CH65), and serum
from a negative control monkey (CH85). CH93, CH63, and
CH65 all neutralized monkeypox virus; however, the
PRNT50 for CH63 was less then 20, and the PRNT for
CH93 and CH65 were 40 and 320, respectively (Fig. 5B).
None of the monkey sera (lowest dilution tested was 1:20)
neutralized more than 70% of the plaques. The same
monkey sera were tested in a vaccinia PRNT. These sera
neutralized vaccinia more efficiently than monkeypox virus
(Fig. 5C). The vaccinia PRNT80/50 titers of CH93, CH63,
and CH65 were 160/320, 80/320, 160/640, respectively
(Fig. 3A, and Fig. 5C). Two vaccinia-specific MAbs were
also tested for capacity to neutralize monkeypox virus. The
vaccinia MAbs included the L1R-specific MAb-7D11 and
the A27L-specific MAb-4B4. MAb-4B4 and MAb-7D11
neutralized both monkeypox virus and vaccinia virus (Fig.
5B and 5C). The PRNT50 titer of MAb-4B4 was 40 for
monkeypox virus and 80 for vaccinia virus. The PRNT80
titer of MAb-7D11 was 40960 for monkeypox virus and
81920 for vaccinia virus (data not shown).
Discussion
Previously we reported that DNA vaccination with a
combination of IMV- and EEV-specific immunogens con-
ferred an enhanced level of protection compared to vacci-
nation with either immunogen alone (Hooper et al., 2000).
Here, we demonstrated that two other IMV- and EEV-
specific immunogens, A27L and B5R, similarly conferred
better protection when administered in combination. In two
independent experiments, vaccination with A27L or B5R
individually protected fewer than half the mice, whereas
vaccination with a combination of the two immunogens
protected 10 of 10 mice in the first experiment and 9 of 10
mice in the second.
DNA vaccination with A27L alone failed to protect de-
spite the production of NAb titers as high as or higher than
those elicited by scarification with live VACV. The NAb
PRNT titers elicited in the A27L DNA-vaccinated mice
were remarkably consistent: in experiments 1, 2, and 3, the
GMTs of the A27L-vaccinated groups were 470, 485, and
470, respectively. The NAb responses in mice scarified with
VACV-CONN in the same three experiments were less
consistent: in experiments 1, 2, and 3, the GMTs were 1174,
243, and 49, respectively. The low PRNT in the experiment
3 scarified group might be attributed to a 3 week, rather than
8 week, duration between scarification and serum collec-
tion.
Despite the relatively robust NAb response elicited by
DNA vaccination with A27L, 90% of the mice did not
survive a VACV-WR, i.p. challenge. This was not expected
because in two published studies, vaccination with E. coli-
expressed A27L protein plus adjuvant protected BALB/c
mice from a VACV-WR, i.p. challenge (Lai et al., 1991;
Demkowitz et al., 1992). In the Lai study, the titer that
neutralized 80% of the plaques (PRNT80) in serum pools
from protected groups ranged from 256–1024; however, in
our study the PRNT80 ranged from 40–640 (data not
shown). Demkowitz reported the presence of NAb after
vaccination with E. coli-expressed protein, but did not pro-
vide titers. It is possible that higher NAb levels can account
for the protection observed in the E. coli-expressed A27L
vaccine studies. Our data indicate that anti-A27L NAb titers
below 1280 are insufficient to protect against a lethal intra-
peritoneal challenge of VACV-WR. Others have reported
that some, but not all, A27L-specific MAbs protected mice
in passive transfer experiments (Czerny and Mahnel, 1990;
Ramirez et al., 2002). The protection observed in passive
transfer studies could be the result of higher antibody con-
centrations achieved by direct transfer of purified antibody,
or in subtle differences in the challenge model. Alterna-
tively, the properties (e.g., epitope specificity, binding af-
finity, isotype) of the NAb response elicited by DNA vac-
cination could be different from those of the protective
MAb. The A27L gene in our vaccine (from VACV-CONN)
differs from the challenge strain, VACV-WR, at three
amino acid positions; however, this strain difference cannot
account for the absence of protection because the sera from
A27L DNA vaccinated mice neutralized VACV-WR (data
not shown). Alternatively, the differences in the nature of
the immune responses elicited by vaccination with exog-
enously expressed protein (plus adjuvant) versus endog-
enously expressed protein (i.e., DNA vaccination) could
account for the different levels of protection.
Our B5R DNA vaccine protection results differ some-
what from those reported previously. Whereas we observed
an overall 37% protection rate after DNA vaccination with
B5R, Galmiche et al. (1999) observed 80% protection rate.
Because different challenge models were used in these stud-
ies (i.e., VACV-WR by i.p. versus VACV-IHD-J by i.n.), it
is not possible to directly compare the results. One might
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expect a greater involvement of the EEV form of vaccinia in
the i.n. model because the course of disease is extended:
peak weight loss and time-to-death was 2 days later in the
i.n. model than in the i.p. model, suggesting the first rounds
of replication are insufficient to cause death. In our study,
there was no correlation between B5R-specific antibody
levels in the B5R-vaccinated mice and survival.
Our previous L1R  A33R data (Hooper et al., 2000)
and the A27L  B5R data reported here are currently the
only studies in which combinations of recombinant vaccinia
immunogens have been tested for protective efficacy in
animal models. Experiments testing the capacity of inacti-
vated vaccinia (IMV) to elicit protective immunity demon-
strated that an immune response to inactivated IMV, includ-
ing neutralizing antibody, was sufficient to protect against
lethal rabbitpox, but was insufficient to protect against in-
tradermal challenge and lesion formation (Boulter et al.,
1971). From these data, the authors concluded that viral
replication and production of EEV was necessary to elicit
protective immunity. In general, our data indicate that vac-
cination with a combination of IMV and EEV-specific im-
munogens confers a greater degree of protection than vac-
cination with only IMV or EEV immunogens. In
experiment 2, Fig. 2A–B, 27 of 30 mice vaccinated with an
IMV/EEV combination survived challenge, whereas only
17 of 40 mice vaccinated exclusively with IMV or EEV
immunogens survived challenge. However, an IMV/EEV
combination was not always necessary for protection be-
cause eight of 10 mice vaccinated with the B5R and A33R
(an EEV/EEV combination) survived; and A33R alone or
L1R alone can provide protection from a lethal challenge
(Hooper et al., 2000).
We have focused on immunogens believed to elicit hu-
moral responses that contribute to protection; however, it is
likely that T-cell responses to as yet unknown vaccinia
immunogens contribute significantly to immunity after
smallpox vaccination. Patients with T-cell deficiency and
apparently normal antibody responses have been diagnosed
with progressive vaccinia virus infections after smallpox
vaccination, suggesting a role of T-cells in controlling vac-
cinia virus infection (O’Connell et al., 1964). We have
evaluated only antibody responses to our four-gene-combi-
nation vaccine; nevertheless, it is possible that one or all of
the immunogens elicit protective T-cell-mediated re-
sponses. Demkowitz et al. (1992) reported that inoculation
of BALB/c with purified E. coli-expressed A27L protein
plus adjuvant not only elicited NAbs, but also elicited cel-
lular proliferative immune responses. To our knowledge,
information on cytotoxic T-cell responses to A27L, L1R,
A33R, or B5R has not been reported.
Having found that vaccination with a combination of
Fig. 5. Antibodies elicited by DNA vaccination with vaccinia-based plas-
mids react with monkeypox virus orthologous proteins. (A) COS cells were
transfected with DNA vaccine plasmids containing the monkeypox virus
L1R, A33R, B5R, A27L ortholog, or empty vector; pMPOX/L1Ro, pM-
POX/A33Ro, pMPOX/B5Ro, pMPOX/A27Lo, (), respectively. RIPA
were performed using serum from a monkey, CH93, vaccinated with the
four-gene-combination (plasmids, pWRG/L1R, pWRG/A33R, pWRG/
B5R, and pWRG/A27L). Serum from a monkey vaccinated with pWRG/
L1R alone, CH63, was used to immunoprecipitate monkeypox virus L1R
ortholog. A no antibody (no Ab) control was included in the monkeypox
virus L1R ortholog RIPA. Molecular mass markers (M) are shown in kDa
on the left and the position of specific vaccinia immunogens are shown on
right. The o (e.g., L1Ro) indicates ortholog. PRNT were performed to
detect (B) MPOV-neutralizing antibodies or (C) vaccinia-neutralizing an-
tibodies in the sera from DNA vaccinated monkeys or relevant MAbs.
Serum samples collected before vaccination (prebleeds) were also tested.
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L1R and A33R, or A27L and B5R, protected mice from
VACV-WR, we reasoned that a candidate vaccine contain-
ing all four genes might result in an even more potent
vaccine. In two independent experiments, a total of 27 of 27
mice vaccinated with the four-gene-combination survived
challenge, with minimal weight loss. Complete protection
was achieved when the four genes were on different gold
beads delivered to adjacent sites on the abdomen, or on
different gold beads mixed together in the same cartridge
and delivered to the same sites on the abdomen. The latter
method indicates that it will be possible to make a single
gene gun cartridge that contains all four genes. These data
are important because we previously found that combining
A33R on the same gold beads as L1R eliminated the im-
munogenicity of L1R (i.e., no NAb response) (Hooper et al.,
2000). We have subsequently found that the interference is
at the level of translation because L1R is not expressed in
cells co-transfected with pWRG/L1R and pWRG/A33R as
measured by RIPA (data not shown). For practical purposes,
this indicates that a gene-based vaccine incorporating A33R
must be designed to minimize delivery of A33R to the same
cells as L1R. We achieved this by loading our plasmids of
interest on different gold beads, then mixing the beads, as
opposed to mixing the DNA then coating gold with the
mixture. We surmise that delivery of the mixed beads re-
sults in fewer cells containing both the L1R and A33R
plasmids.
The promising efficacy of this four-gene-combination
vaccine in mice prompted us to test the vaccine for immu-
nogenicity in a nonhuman primate model. We determined
that vaccination of rhesus monkeys with the four-gene-
combination DNA vaccine elicited antibodies against at
least three of the four immunogens, as measured by gene-
specific assays (i.e., RIPA, B5R-specific ELISA, A33R-
specific ELISA). An anti-L1R response was not specifically
detected in the four-gene-combination vaccinated monkeys;
however, we know the pWRG/L1R plasmid is immuno-
genic in rhesus because monkeys vaccinated with pWRG/
L1R alone developed NAb responses (PRNT50 ranged from
160–640) and all had sufficient antibody levels to immu-
noprecipitate the L1R protein, as well as the monkeypox
virus L1R ortholog.
By redundant targeting of both the IMV and EEV, it may
be possible to develop a gene-based vaccine that protects
not only against vaccinia but also against other orthopox
viruses. Comparison of VACV-CONN A27L, A33R, L1R,
and B5R genes with the orthologous genes in monkeypox
virus and variola virus indicate that all four genes encode
highly conserved amino acids. VACV and MPOV-279
A27L, A33R, L1R, and B5R orthologous proteins are 95%,
94%, 98%, and 97% identical, respectively; VACV and
VARV-IND are 97%, 94%, 99%, and 93% identical, re-
spectively. More importantly, we found that DNA vaccina-
tion of rhesus monkeys with the VACV A27L, A33R, L1R,
and B5R genes elicited antibodies that cross-reacted with all
four monkeypox virus orthologs as measured by RIPA and
PRNT. We did not test the capacity of these antibodies to
bind to the variola virus orthologs; however, sequence anal-
ysis indicates that vaccinia virus is actually as or more
similar to variola virus than monkeypox virus for A27L,
A33R, and L1R.
Rhesus monkeys are susceptible to monkeypox virus and
it is possible to protect these animals by scarifying with the
human smallpox vaccine (McConnell et al., 1964). Future
investigations will determine if DNA vaccination with the
four-gene-combination can protect rhesus monkeys against
monkeypox. Depending on the outcome of challenge stud-
ies, a gene-based vaccine could be improved by adding
additional protective immunogens (e.g., protective T-cell
epitopes) and/or by changing the vector, route of adminis-
tration, vaccination schedule, etc. Also, it will be important
to build assays of cell-mediated immunity into future stud-
ies. Work along these lines may ultimately provide an al-
ternative poxvirus vaccine bereft of the known side effects
and serious adverse reactions (e.g., inadvertent inoculation
including ocular implantation, erythema multiform, eczema
vaccinatum, vaccinial keratitis, generalized vaccinia, pro-
gressive vaccinia, and postvaccinial encephalitis) associated
with the currently licensed live vaccinia-based smallpox
vaccine.
Materials and methods
Viruses and cells
Vaccinia virus, strain Connaught (VACV-CONN) (a
vaccine strain derived from the New York City Board of
Health strain) (McClain et al., 1997) and strain Western
Reserve (VACV-WR) (ATCC VR-119), and monkeypox
virus strain Zaire 79 (MPOV-Z79) (provided by John Hug-
gins, USAMRIID) were maintained in VERO cell (ATCC
CRL-1587) monolayers grown in Eagle minimal essential
medium, containing 5% heat-inactivated fetal bovine serum,
1% antibiotics (100 U/ml penicillin, 100 mg/ml streptomy-
cin, and 50 mg/ml gentamicin), 10 mM HEPEs (cEMEM).
COS cells (ATCC CRL 1651), used for transient expression
experiments, were maintained in cEMEM.
Antibodies
One L1R-specific monoclonal antibody (MAb-7D11),
and one A27L-specific monoclonal antibody (MAb-4B4),
as ascitic fluids, were used. During the course of the studies
reported here, we identified the target of MAb-4B4 using
our plasmid expressing A27L, pWRG/A27L (data not
shown). VACV-CONN hyperimmune mouse ascitic fluid
(VACV HMAF) and normal human serum was also used. A
hantavirus-specific monoclonal antibody (MAb-3d7) was
used as a negative control in some experiments.
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Cloning orthopox virus genes into naked-DNA expression
plasmids
pWRG/A27L and pWRG/B5R. VACV-CONN DNA was pu-
rified by standard methods and used as template for PCR.
PCR primer design was based on the published VACV-
Copenhagen sequence (accession number M35027). The
A27L forward primer was 5-GCCGGCGGCCGCGCCAC-
CATGGACGGAACTCTTTTCCCCGGA and the reverse
primer was 5-GCGCAGATCTTTACTCATATGGACGC-
CGTCCAG; the B5R forward primer was 5-GCCGGCG-
GCCGCGCCACCATGAAAACGATTTCCGTTGTTACG
and the reverse primer was 5-GCGCAGATCTTTACGG-
TAGCAATTTATGGAACT. A NotI site (italicized) was
incorporated in the forward primers and a BglII site (itali-
cized) was incorporated into the reverse primers. Start
codons are shown in bold. The A27L and B5R genes were
PCR-amplified using VENT polymerase (NEB), cut with
NotI and BglII, and cloned into the NotI-BglII site of
pWRG7077 (Schmaljohn et al., 1997).
pWRG/L1R (x) and pWRG/A33R (x). Previously we had
cloned the VACV-CONN L1R and A33R genes into the
NotI site of pWRG7077 (Hooper et al., 2000). During the
course of subsequent studies, we discovered that there were
100 cloning artifact nucleotides (derived from SIV nef
gene) between the BamHI and BglII sites of the pWRG7077
vector. To remove those nucleotides from our L1R and
A33R constructs for future vaccine studies, we recloned the
VACV-CONN L1R and A33R genes using a strategy that
removed the unwanted sequence. The L1R forward primer
was 5-GCCGGCGGCCGCGCCACCATGGGTGCCG-
CAGCAAGCATACAG and the reverse primer was 5-
GCGCAGATCTTCAGTTTTGCATATCCGTGGTAG; the
A33R forward primer was 5-GCCGGCGGCCGCGCCAC-
CATGATGACACCAGAAAACGACGAA and the reverse
primer was 5-GCGCAGATCTTTAGTTCATTGTTTTAA-
CACAAA. The L1R and A33R genes were PCR-amplified
from VACV-CONN DNA, cut with NotI and BglII, and
cloned into the NotI-BglII site of pWRG7077 to yield
pWRG/L1R (x) and pWRG/A33R (x), respectively. In this
paper, these plasmids will be referred to as pWRG/L1R and
pWRG/A33R, to avoid confusion.
pMPOX/A27Lo, pMPOX/A33Ro, pMPOX/L1Ro, pMPOX/B5Ro.
Monkeypox virus (MPOV-Z79) DNA was purified by stan-
dard methods. The aforementioned primers used to PCR-
amplify and clone the VACV-CONN A27L, and L1R were
used to clone the monkeypox virus orthologous genes. The
monkeypox virus A33R gene ortholog (A35R) could not be
amplified using the VACV-based primers. We designed
new primers based on the DNA sequence from the recently
published monkeypox virus, strain Zaire 96 genome (Shch-
elkunov et al., 2001). The primers were designed to anneal
to the external sequence flanking the A33R ortholog. The
forward primer was 5-GCCGGCGGCCGCGCCACC-
ATATAAATAACATTTATTATCATG, and the reverse
primer was 5-GCGCAGATCTTATTAAGCGATTTCATT-
TATTTA. The gene was PCR-amplified using VENT, cut
with NotI and BglII, and cloned into the NotI-BglII site of
pWRG7077. To clone the monkeypox virus B5R ortholog,
we used a modified pWRG7077 vector in which the NotI-
BglII sequence had been excised and replaced with a 100
nucleotide multiple cloning site (5-GGCCGCTAGTTAT-
TGCTCAGCGGTGGCAGCAGCCAACTCACCTTCCTT-
TCCCCCTTTGTTAGCAGCCGGATCAAGCTTCGAAG-
CTTCGAATTCCATGGTACCAGCTGCA). We used the
VACV-based B5R forward primer (see above) and a new
reverse primer, 5-GCGCTTCGAATTACGGTAGCAATT-
TATGGAACT, containing a BstBI site (italicized). The
gene was PCR-amplified using PLATINUM Tag High Fi-
delity polymerase (Invitrogen), cut with NotI and BstBI, and
cloned into the NotI-BstBI site of pWRG7077 (NotI-BglII/
MCS).
The VACV-CONN A27L and B5R genes, and the
MPOV-Z79 A27L, A33R, L1R, and B5R orthologous genes
were PCR amplified and sequenced directly using an ABI
377 or 3100 sequencer. In addition, the cloned genes and
cloning junctions were sequenced for each DNA vaccine
plasmid construct. Sequences were submitted to GeneBank.
Transient expression
Plasmid DNA was transfected into COS cell monolayers
(60–80% confluent) using Fugene6 reagent as described by
the manufacturer. After 24 hr, monolayers were radiola-
beled with Promix (200 mCi per T-25 flask, 35S-methionine
and [35S]-cysteine; Amersham) for 4 hr and immunopre-
cipitated as described previously (Hooper et al., 2000).
Transfected cells were lysed on ice for 5 min with a mod-
ified RIPA buffer: 4% Zwittergent (Calbiochem) 0.5 M
NaCl, 1 mM EDTA, 10 mM Tris, pH 8, and protease
inhibitors (Complete; Boehringer Mannheim). Lysates were
combined with the indicated antibody (previously incubated
1 h with unlabeled COS cell lysate) and incubated overnight
at 4°C. Lysate-antibody mixtures were combined with pro-
tein A sepharose (CL-4B; Sigma), incubated at 4°C for 30
min, and then washed three times with lysis buffer and once
with 10 mM Tris, pH 8.0. Sample buffer (125 mM Tris [pH
8.0], 1% sodium dodecyl sulphate, 10% glycerol, 0.01%
bromophenol blue containing 2% 2-mercaptoethanol) was
added and the samples were boiled for 2 min. Samples were
run on 4 to 12% bis-Tris sodium dodecyl sulphate poly-
acrylamide gel electrophoresis gradient gels with 2-N (mor-
pholino) ethane sulfonic acid running buffer (NuPAGE), at
a 200-V constant voltage.
Vaccination with the gene gun
Cartridges for the gene gun were prepared as described
previously (Eisenbraun et al., 1993; Schmaljohn et al.,
1997; Hooper et al., 2000). Briefly, plasmid DNA was
precipitated onto 2 m diameter gold beads (Degussa),
1–5 g of DNA per 1 mg of gold, which were then coated
on the inner surface of Tefzel tubing (McMaster-Carr).
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Cartridges containing the four-gene-combination were
made by loading the four different plasmid preparations on
gold in separate tubes. After precipitating the DNA and
washing the gold, we pooled the four DNA gold slurries
together, mixed, and used them to coat Tefzel tubing. The
tubing was cut into 0.5 inch cartridges. When completed,
each cartridge contained 0.5–1 g of DNA coated on 0.5
mg of gold.
To vaccinate animals, abdominal fur was removed with
clippers and DNA-coated gold was administered to non-
overlapping sites on the abdominal epidermis by using the
gene gun (Powderject Delivery Device, Powderject, Inc.) at
400 p.s.i. as described previously (Pertmer et al., 1995).
When the animal was vaccinated with a single immunogen
(i.e., one plasmid construct), mice received two and mon-
keys received eight gene gun administrations. Mice vacci-
nated with two immunogens in different cartridges received
one gene gun administration per plasmid. When the animal
was vaccinated with four immunogens in different car-
tridges, mice received one and monkeys received two ad-
ministrations per plasmid. Mice vaccinated with four im-
munogens in the same cartridge received four gene gun
administrations.
Vaccination with vaccinia virus vaccines
Mice scarification. A 10 l drop of PBS containing 8 106
PFU of VACV-CONN was placed 1 cm from the base of
the tail and then scratched into the tail (15 3 mm
scratches) using a needle on a tuberculin syringe.
Monkeys vaccinated subcutaneously with live vaccinia
virus. Rhesus macaques were vaccinated with a recombi-
nant vaccinia virus (expressing the hantavirus S and M
genes) by the method used to vaccinate humans in a phase
II clinical trial (McClain et al., 2000). The vaccine consisted
of 3.4  107 PFU in 0.5 ml of PBS injected subcutaneously
into the right lateral upper arm with a 26 G 3/8-in. needle.
After 42 days, the monkeys received an identical vaccina-
tion on the left arm. These monkeys were part of a hanta-
virus DNA vaccine study which was reported previously
(Hooper et al., 2001).
Monkey vaccination with vaccinia virus (Dryvax) by
scarification. Rhesus macaques were vaccinated with the
human smallpox vaccine (Dryvax, Wyeth Laboratories,
Marietta, PA) by the protocol outlined in the vaccine insert.
The vaccine (control no. 4008257) was reconstituted in the
diluent provided (lot no. 4008258). The vaccination site
(right lateral upper arm) was prepared by removing the hair
using clippers, and wiped with an alcohol swab. A bifur-
cated needle was dipped in the vaccine and used to admin-
ister the vaccine by 15 pricks. Successful vaccination was
confirmed 1 week after administration by the presence of a
characteristic lesion.
Plaque reduction neutralization test (PRNT)
The vaccinia PRNT using VACV-CONN infected-cell
lysate as the virus was performed exactly as described
previously (Hooper et al., 2000). Monkeypox virus PRNT
were performed in an identical manner to the vaccinia
PRNT except MPOV-Z79 infected-cell lysate was the virus
source, and the infections were stained with crystal violet on
day 5 instead of day 3.
Vaccinia ELISA
Vaccinia infected-cell-lysate ELISA. Vaccinia-infected-cell
lysate was prepared as follows. Vero cell monolayers grown
in roller bottles were infected with VACV-CONN at a
multiplicity of infection of 1, cell monlayers were harvested
on day 4, cells were pelleted by spinning 90 min at 10,000
g, the pellet was resuspended in 10 mM Tris pH 8 (2 ml per
roller bottle), Dounce homogenized, and the nuclei were
removed by spinning 5 min at 1,000 g. The lysate was
subjected to three rapid freeze-thaws, sonicated for 1 min on
ice three times, and pelleted by spinning 40 min at 20,000 g.
The pellet was resuspended in 10 mM Tris pH 8.0 (0.5 ml
per roller bottle) and titration experiments were performed
to determine the concentration of vaccinia infected-cell-
lysate antigen to be used in ELISA.
Vaccinia purified virion ELISA antigen. The vaccinia in-
fected-cell-lyate (above) was purified on 20–60% (weight/
weight sucrose/TE) sucrose gradients spun at 82.7K g for
2.5 hr.
ELISA. 96-well ELISA plates (Costar) were coated with
antigen and dried overnight. Mock antigen preparations
were prepared in an identical manner as the actual antigens;
however, uninfected monolayers were used. Plates were
washed with wash buffer (PBS 0.05% tween-20) and then
blocked 1 h at 37°C with blocking buffer (wash buffer
containing 5% fetal bovine serum and 3% goat serum).
Serum samples diluted in blocking buffer were added 100
l per well to antigen or mock antigen containing wells and
incubated 1 h at 37°C. Plates were washed three times and
100 l per well of the appropriate peroxidase-labeled sec-
ondary antibody was added (peroxidase-labeled goat anti-
mouse, IgG [Sigma], peroxidase-labeled goat anti-monkey
IgG [KPL]). After a 1 h incubation at 37°C, the plates were
washed and incubated 30 min at room temperature with 100
l of 2,2-azino bis-3-ethylbenzthiazoline-6-sulfonic acid
(ABTS) substrate. The reactions were stopped by adding
100 l per well of 0.2 N phosphoric acid and the O.D. at
405 nm was determined by an ELISA plate reader. For each
serum dilution series, O.D. values from mock antigen wells
were subtracted from the experimental values to give spe-
cific O.D. values. Each specific O.D. value represented the
average value of two independent dilution series. End-point
titers were determined as the highest dilution with an ab-
sorbance value greater than the mean absorbance value from
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negative control plasmid (pWRG7077)-vaccinated animals
plus three standard deviations.
Anti-A33R and anti-B5R ELISA
The anti-A33R ELISA was described previously
(Hooper et al., 2000). The anti-B5R ELISA was performed
in an identical manner except the pWRG/A33R DNA was
replaced with the pWRG/B5R DNA. Briefly, COS cell
monolayers, grown in 96 well cell culture plates, were
transfected with pWRG/A33R or pWRG/B5R (0.2 mg/well)
using Fugene 6 or were mock transfected. After 24 h the
monolayers were fixed with 1:1 acetone:methanol for 2 min,
rinsed with PBS, incubated 1 h with primary antibody
diluted in PBS  3% FBS, rinsed with PBS, incubated 30
min with peroxidase labeled goat anti-mouse antibody
(SIGMA, cat. no. A4416) or peroxidase-labeled goat anti-
monkey antibody (KPL, cat. no. 074-11-021) diluted in PBS
 3% FBS, rinsed, and finally, incubated with ABTS sub-
strate as described above. After 30 min, reactions were
stopped and O.D. values were determined as described
above. Optical density values from mock-transfected wells
were subtracted from those of transfected wells to determine
the specific O.D. for each sample. End-point titers were
determined as the highest dilution with an absorbance value
greater than the mean absorbance value from negative con-
trol plasmid (pWRG7077) -vaccinated animals plus three
standard deviations.
A33R and B5R immunostaining
Anti-A33R and anti-B5R antibodies in the serum from
vaccinated monkeys were detected by the following immu-
nostaining procedure. Six-well plates containing COS cell
monolayers at80% confluency were transfected with 2 g
of either pWRG/A33R, or pWRG/B5R, or mock transfected
with Fugene 6. After 24 hr, the monolayers were fixed
with 1:1 acetone:methanol for 2 min, rinsed with PBS,
incubated 1 h with serial twofold dilutions of primary an-
tibody diluted in PBS  3%FBS, rinsed with PBS, incu-
bated 30 min with peroxidase-labeled goat anti-monkey
antibody (KPL) diluted in PBS plus 3% fetal bovine serum,
rinsed, and incubated with dianisidine (SIGMA) substrate
as described by Roper et al., 1996. Endpoint titers were
determined by identifying the highest antibody dilution that
resulted in positively stained (brown) cells.
Challenge experiment
Mice were injected i.p. with 0.2 ml of PBS containing 5
 108 PFU of VACV-WR (12 LD50) (clarified infected-cell
lysate) with a 0.5 mm 16 mm needle. Mice were weighed
before challenge and on each day thereafter for 2 weeks.
Terminal bleeds were obtained from survivors 3 to 4 weeks
after challenge. This research was conducted in accordance
with procedures described in the Guide for the Care and Use
of Laboratory Animals (National Institute of Health, 1996).
The facilities are fully accredited by the American Associ-
ation for Accreditation of Laboratory Animal Care.
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